Lindsay R M, Jamieson N S, Walker S A, McGuigan C C, Smith W, Baird J D
University of Edinburgh Department of Medicine, Western General Hospital, UK.
Diabetologia. 1998 May;41(5):516-23. doi: 10.1007/s001250050940.
Previous studies demonstrating reduced plasma concentrations of ascorbic acid (AA) in diabetes and interactions between this vitamin and biochemical mechanisms such as synthesis of structural proteins, oxidative stress, polyol pathway and nonenzymatic glycation of proteins suggest that disturbed AA metabolism may be important in the pathogenesis of diabetic microangiopathy. However, limited information is available on the concentration of AA in tissues which develop diabetic complications. This study demonstrates reduced renal but not sciatic nerve or plasma AA concentration in two animal models of insulin-dependent diabetes mellitus, namely the STZ-diabetic rat and the spontaneously diabetic BB rat. Decreased lens AA concentration was also observed in STZ-diabetic rats. Improvement of glycaemic control by insulin treatment (albeit insufficient to achieve normoglycaemia) partially corrected lens and renal AA concentration in STZ-diabetic rats. AA treatment increased kidney and lens AA concentrations of STZ-diabetic and non-diabetic rats and corrected the abnormalities observed for untreated diabetic rats. Sciatic nerve AA concentration was not increased by AA treatment in any group. Tissue ratios of dehydroascorbic acid (DHAA)/AA, one index of oxidative stress, were not different between the diabetic and non-diabetic groups and were unaltered by AA supplementation. AA treatment of STZ-diabetic rats had no effect on elevated tissue concentrations of glucose, sorbitol and fructose or reduced myo-inositol concentration. The effect of reduced tissue AA levels in diabetes on either collagen synthesis or ability to combat increased free radical production is not known. However, correction of abnormal kidney and lens AA concentrations in experimental diabetes by AA supplementation suggests that if AA does have a role in the development or progression of the renal and ocular complications of diabetes, this treatment could be beneficial.
先前的研究表明,糖尿病患者血浆中抗坏血酸(AA)浓度降低,且该维生素与结构蛋白合成、氧化应激、多元醇途径以及蛋白质非酶糖基化等生化机制之间存在相互作用,这表明AA代谢紊乱可能在糖尿病微血管病变的发病机制中起重要作用。然而,关于发生糖尿病并发症组织中AA浓度的信息有限。本研究表明,在两种胰岛素依赖型糖尿病动物模型,即链脲佐菌素诱导糖尿病大鼠和自发性糖尿病BB大鼠中,肾脏AA浓度降低,但坐骨神经和血浆AA浓度未降低。在链脲佐菌素诱导糖尿病大鼠中也观察到晶状体AA浓度降低。胰岛素治疗改善血糖控制(尽管不足以实现血糖正常)部分纠正了链脲佐菌素诱导糖尿病大鼠晶状体和肾脏的AA浓度。AA治疗增加了链脲佐菌素诱导糖尿病大鼠和非糖尿病大鼠肾脏和晶状体的AA浓度,并纠正了未治疗糖尿病大鼠所观察到的异常。任何组中AA治疗均未增加坐骨神经AA浓度。氧化应激指标之一的脱氢抗坏血酸(DHAA)/AA组织比值在糖尿病组和非糖尿病组之间无差异,且AA补充未改变该比值。链脲佐菌素诱导糖尿病大鼠的AA治疗对升高的组织葡萄糖、山梨醇和果糖浓度或降低的肌醇浓度无影响。糖尿病时组织AA水平降低对胶原蛋白合成或对抗自由基产生增加能力的影响尚不清楚。然而,通过补充AA纠正实验性糖尿病中肾脏和晶状体AA浓度异常表明,如果AA确实在糖尿病肾脏和眼部并发症的发生或发展中起作用,这种治疗可能有益。